Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Treatment of atopic dermatitis with probiotic L. lactis lysate - A double-blinded, placebo-controlled pilot study
  • +1
  • Ville Salo,
  • Anita Remitz,
  • Antti Lauerma,
  • Alexander Salava
Ville Salo
Helsinki University Hospital and University of Helsinki

Corresponding Author:[email protected]

Author Profile
Anita Remitz
Helsinki University Hospital and University of Helsinki
Author Profile
Antti Lauerma
Helsinki University Hospital and University of Helsinki
Author Profile
Alexander Salava
Helsinki University Hospital and University of Helsinki
Author Profile

Abstract

Background: Microbiome-targeted treatments have been investigated in atopic dermatitis (AD). We aimed to investigate the use of probiotic Lactococcus lactis lysate cream in AD. Methods: 13 patients with mild-to-moderate AD were treated with differently concentrated probiotic creams (3%, 10% and 30%) or placebo cream for 4 weeks. Disease severity (EASI, IGA), epidermal barrier function (TEWL) and patient-reported impact (DLQI, POEM, ADCT, pruritus and sleep disturbance VAS) were measured at baseline, 4 and 8 weeks. Comprehensive clinical data and laboratory values (blood eosinophil count, total serum IgE-levels and specific IgEs to aeroallergens) were obtained. Results: Comparison of the treatment groups showed no clear differences regarding AD severity (EASI, p=0.76, CI: 0.65-1.00), epidermal barrier dysfunction (TEWL, p=0.37, CI: 0.19-0.73) or patient-reported impact (DLQI, p=0.76, CI: 0.65-1.00; POEM, p=0.76, CI: 0.35-0.88; ADCT, p=0.72, CI: 0.65-1.00; pruritus VAS 0.67, CI: 0.55-1.00; sleep disturbance VAS, p=1.00, CI: 0.79-1.00) between different probiotic lysate concentrations and placebo. The probiotic lysate cream was well tolerated and there were no significant adverse effects. Limitations were a small and heterogenous patient groups and a relatively short follow-up with no evaluation of long-term effects. Conclusions: Topical probiotic L. lactis lysate cream showed no clear differences between the tratment groups in mild-to-moderate AD. Although topical probiotics have been reported effective in a limited number of studies, more placebo-controlled clinical studies are needed to explore their potential role in the treatment of AD.